Estimated cytomegalovirus seroprevalence in the general population of the United States and Canada.

Autor: Dana Flanders W; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.; Epidemiologic Research & Methods, LLC, Southport, NC, USA., Lally C; Epidemiologic Research & Methods, LLC, Southport, NC, USA., Dilley A; Epidemiologic Research & Methods, LLC, Southport, NC, USA., Diaz-Decaro J; Epidemiology, Moderna, Inc., Cambridge, MA, USA.
Jazyk: angličtina
Zdroj: Journal of medical virology [J Med Virol] 2024 Mar; Vol. 96 (3), pp. e29525.
DOI: 10.1002/jmv.29525
Abstrakt: Seroprevalence data for cytomegalovirus (CMV), a widespread virus causing lifelong infection, vary widely, and contemporary data from the United States (US) and Canada are limited. Utilizing a modeling approach based on a literature review (conducted August, 2022) of data published since 2005, we determine age-, sex-, and country-specific CMV seroprevalence in the general US and Canadian populations. Sex-specific data were extracted by age categories, and a random-effects meta-regression model was used to fit the reported data (incorporating splines for the US). Seven studies reported US CMV seroprevalence (both sexes, aged 1‒89 years); all used National Health and Nutrition Examination Survey data. Due to limited population-based studies, Canadian estimates were modeled using other limited country data. In both countries, modeled seroprevalence estimates increased with age and were higher in females versus males (US: 49.0% vs. 41.6% at 18‒19 years; 61.5% vs. 50.0% at 38‒39 years; Canada: 23.7% vs. 13.7% at 18‒19 years; 32.6% vs. 22.6% at 38‒39 years). Notably, by young adulthood, one-half of US and one-quarter of Canadian females have acquired CMV. The observed differences in CMV seroprevalence in the US and Canada may partially reflect variations in general population characteristics.
(© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: